Literature DB >> 20511554

Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.

Stefani Spranger1, Miran Javorovic, Maja Bürdek, Susanne Wilde, Barbara Mosetter, Stefanie Tippmer, Iris Bigalke, Christiane Geiger, Dolores J Schendel, Bernhard Frankenberger.   

Abstract

In this paper, we describe a new method for preparation of human dendritic cells (DCs) that secrete bioactive IL-12(p70) using synthetic immunostimulatory compounds as TLR7/8 agonists. Monocyte-derived DCs were generated using a procedure that provided mature cells within 3 d. Several maturation mixtures that contained various cytokines, IFN-gamma, different TLR agonists, and PGE(2) were compared for impact on cell recovery, phenotype, cytokine secretion, migration, and lymphocyte activation. Mixtures that included the TLR7/8 agonists R848 or CL075, combined with the TLR3 agonist polyinosinic:polycytidylic acid, yielded 3-d mature DCs that secreted high levels of IL-12(p70), showed strong chemotaxis to CCR7 ligands, and had a positive costimulatory potential. They also had excellent capacity to activate NK cells, effectively polarized CD4(+) and CD8(+) T cells to secrete IFN-gamma and to induce T cell-mediated cytotoxic function. Thereby, mature DCs prepared within 3 d using such maturation mixtures displayed optimal functions required for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511554     DOI: 10.4049/jimmunol.1000060

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 2.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

Review 3.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 4.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

Review 5.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

6.  In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC.

Authors:  Maryam Nourizadeh; Farimah Masoumi; Ali Memarian; Kamran Alimoghaddam; Seyed Mohammad Moazzeni; Marjan Yaghmaie; Jamshid Hadjati
Journal:  Target Oncol       Date:  2013-07-14       Impact factor: 4.493

Review 7.  Dendritic cells: The warriors upfront-turned defunct in chronic hepatitis C infection.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-09-08

8.  MHC class I and II peptide homology regulates the cellular immune response.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Jonathan Vazquez-Perez; Colby J Hofferek; Scott A Weldon; Yunyu Baig; Indira Vedula; Jonathan M Levitt; William K Decker
Journal:  FASEB J       Date:  2020-04-16       Impact factor: 5.191

9.  Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Authors:  Anne Flörcken; Joachim Kopp; Antje van Lessen; Kamran Movassaghi; Anna Takvorian; Korinna Jöhrens; Markus Möbs; Constanze Schönemann; Birgit Sawitzki; Karl Egerer; Bernd Dörken; Antonio Pezzutto; Jörg Westermann
Journal:  Hum Vaccin Immunother       Date:  2013-03-04       Impact factor: 3.452

10.  Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.

Authors:  Maja Bürdek; Stefani Spranger; Susanne Wilde; Bernhard Frankenberger; Dolores J Schendel; Christiane Geiger
Journal:  J Transl Med       Date:  2010-09-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.